107. Juvenile idiopathic arthritis Clinical trials / Disease details
Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02592434 (ClinicalTrials.gov) | June 10, 2016 | 14/8/2015 | Efficacy Study Of Tofacitinib In Pediatric JIA Population | EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS | Juvenile Idiopathic Arthritis | Drug: CP-690,550 (tofacitinib);Other: placebo | Pfizer | NULL | Completed | 2 Years | 17 Years | All | 225 | Phase 3 | United States;Argentina;Australia;Belgium;Brazil;Canada;Israel;Mexico;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;Chile;Germany;South Africa;Switzerland |